Galapagos (NASDAQ:GLPG)‘s stock had its “neutral” rating restated by research analysts at UBS Group in a research report issued on Monday, The Fly reports.
Several other brokerages have also recently issued reports on GLPG. Bank of America raised Galapagos from an “underperform” rating to a “neutral” rating and boosted their price objective for the company from $93.00 to $94.00 in a report on Tuesday, February 23rd. Maxim Group cut Galapagos from a “buy” rating to a “hold” rating in a report on Wednesday, February 10th. Smith Barney Citigroup reissued a “buy” rating on shares of Galapagos in a report on Thursday, December 17th. Bryan, Garnier & Co cut Galapagos from a “buy” rating to a “sell” rating in a report on Thursday, December 17th. Finally, Barclays reaffirmed an “equal weight” rating on shares of Galapagos in a report on Tuesday, March 2nd. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $150.08.
Shares of GLPG stock opened at $78.30 on Monday. The stock has a market cap of $5.13 billion, a PE ratio of -11.86 and a beta of 0.76. The business has a 50-day simple moving average of $80.85 and a 200-day simple moving average of $106.48. Galapagos has a 52-week low of $74.51 and a 52-week high of $233.14.
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, and psoriatic arthritis.
See Also: What is the CAC 40 Index?
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.